
    
      The objectives of the study are:

        1. to improve the diagnosis of overactive bladder using a non-invasive technology (urine
           proteomics) and

        2. to study how potential urine biomarkers changes with overactive bladder symptoms after
           patients have been treated with fesoterodine, an FDA approved drug for the treatment of
           overactive bladder.
    
  